10 Best Seelos Therapeutics Alternatives & Competitors (2026)

COMPASS Pathways develops psilocybin-based therapies for treatment-resistant depression with a focus on large Phase 3 trials and therapist-supported sessions. Its longer-duration psychedelic experience contrasts with Gilgamesh's short-acting 5-HT2AR agonist designed for a 2-hour window and potential scalability advantages post-AbbVie acquisition.

ATAI invests in and develops multiple mental health compounds including ketamine derivatives and ibogaine analogs. While broader in scope than Gilgamesh, ATAI previously acquired Gilgamesh founders' earlier companies, creating direct lineage overlap in psychedelic and ibogaine chemistry.

MindMed advances MM-120, a lysergide d-tartrate for anxiety disorders, and other psychedelic-inspired candidates. Its focus on regulated psychedelic sessions differs from Gilgamesh's emphasis on non-hallucinogenic neuroplastogens and oral NMDAR antagonists suitable for at-home use.

Cybin develops deuterated tryptamine analogs for depression and anxiety with improved pharmacokinetics. Its shorter-acting candidates share some mechanistic overlap with Gilgamesh's Bretisilocin but lack the same level of big-pharma acquisition validation to date.

Delix specializes in non-hallucinogenic psychoplastogens targeting structural brain plasticity. Its approach closely mirrors Gilgamesh's AbbVie-partnered neuroplastogen program, though Delix remains independent without equivalent late-stage partnership announcements.

Beckley Psytech develops synthetic 5-MeO-DMT and other short-acting psychedelics for depression. Its emphasis on rapid-onset, shorter-duration compounds parallels Gilgamesh's 5-HT2AR strategy but without the same disclosed big-pharma exit.

Small Pharma advances SPL026, a DMT-based short-acting psychedelic for depression. Its pharmacokinetic profile resembles Gilgamesh's Bretisilocin yet remains pre-partnership compared to the AbbVie-validated asset.

Lundbeck develops established psychiatric medications and has explored novel mechanisms for depression. As a large pharma, it offers approved products and global reach unlike Gilgamesh's early-clinical NCE pipeline focused on plasticity mechanisms.

J&J markets Spravato (esketamine) nasal spray for depression. Its approved, monitored administration model contrasts with Gilgamesh's pipeline goal of low-dissociation oral agents potentially suitable for at-home psychiatric treatment.